Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features

Abstract

VEGFR TKIs, especially sunitinib, are active and tolerated by mRCC patients with poor risk features.

Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features

“…The 88 patients who had three or more poor prognostic features according to the ARCC trial were included in this study. Of the 85 patients with measurable lesions, the ORR was 22 % with a disease control rate of 56 % [12]. The median OS was 9.3 months (95 % CI 7.1-11.5 months), and most toxicity profiles were consistent with previous studies [12].…”

“…We previously reported a retrospective study on the efficacy of VEGFR TKIs in 88 patients with poor-risk features, as determined by the ARCC trial [12]. VEGFR TKIs were active in this group; the median OS was 9.3 months and median time to progression was 5.0 months [12]. However, 76 patients (86 %) received sunitinib and only two patients (2 %) received pazopanib in that study.…”

“…All of these earlier studies included a small proportion of patients with poor-risk RCC and were limited by the lack of any subgroup analysis of such cases. We previously reported a retrospective study on the efficacy of VEGFR TKIs in 88 patients with poor-risk features, as determined by the ARCC trial [12]. VEGFR TKIs were active in this group; the median OS was 9.3 months and median time to progression was 5.0 months [12].…”

“…Of the 85 patients with measurable lesions, the ORR was 22 % with a disease control rate of 56 % [12]. The median OS was 9.3 months (95 % CI 7.1-11.5 months), and most toxicity profiles were consistent with previous studies [12]. These studies showed that VEGFR TKIs were active and well tolerated by mRCC patients with poor-risk features but all were retrospective, and there were no data on the efficacy of pazopanib.…”

Use of sunitinib in patients with metastatic kidney cancer in real clinical practice

“…Независимыми прогностическими фак-торами, оказывавшими влияние на ОВ, были нейтро-филез, наличие костных метастазов и метастазов в лимфатических узлах, в то время как фактор наличия нефрэктомии в анамнезе не оказывал влияния. В за-ключение авторы отметили, что ингибиторы тирозин-киназ, и в частности сунитиниб, эффективны и хоро-шо переносятся больными мПКР с неблагоприятными факторами прогноза [9].…”